8
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      High PTX3 expression is associated with a poor prognosis in diffuse large B‐cell lymphoma

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tumor‐associated macrophages (TAMs) are associated with a poor prognosis of diffuse large B‐cell lymphoma (DLBCL). As macrophages are heterogeneous, the immune polarization and their pathological role warrant further study. We characterized the microenvironment of DLBCL by immunohistochemistry in a training set of 132 cases, which included 10 Epstein–Barr virus‐encoded small RNA (EBER)‐positive and five high‐grade B‐cell lymphomas, with gene expression profiling in a representative subset of 37 cases. Diffuse large B‐cell lymphoma had a differential infiltration of TAMs. The high infiltration of CD68 (pan‐macrophages), CD16 (M1‐like), CD163, pentraxin 3 (PTX3), and interleukin (IL)‐10‐positive macrophages (M2c‐like) and low infiltration of FOXP3‐positive regulatory T lymphocytes (Tregs) correlated with poor survival. Activated B cell‐like DLBCL was associated with high CD16, CD163, PTX3, and IL‐10, and EBER‐positive DLBCL with high CD163 and PTX3. Programmed cell death‐ligand 1 positively correlated with CD16, CD163, IL‐10, and RGS1. In a multivariate analysis of overall survival, PTX3 and International Prognostic Index were identified as the most relevant variables. The gene expression analysis showed upregulation of genes involved in innate and adaptive immune responses and macrophage and Toll‐like receptor pathways in high PTX3 cases. The prognostic relevance of PTX3 was confirmed in a validation set of 159 cases. Finally, in a series from Europe and North America ( GSE10846, R‐CHOP‐like treatment, n = 233) high gene expression of PTX3 correlated with poor survival, and moderately with CSF1R, CD16, MITF, CD163, MYC, and RGS1. Therefore, the high infiltration of M2c‐like immune regulatory macrophages and low infiltration of FOXP3‐positive Tregs is associated with a poor prognosis in DLBCL, for which PTX3 is a new prognostic biomarker.

          Abstract

          This research focused on the analysis of several macrophage and regulatory T lymphocyte markers in diffuse large b‐cell lymphoma. We found that high PTX3 expression correlated with poor prognosis of the patients.

          Related collections

          Most cited references65

          • Record: found
          • Abstract: found
          • Article: not found

          Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

          Although genomewide RNA expression analysis has become a routine tool in biomedical research, extracting biological insight from such information remains a major challenge. Here, we describe a powerful analytical method called Gene Set Enrichment Analysis (GSEA) for interpreting gene expression data. The method derives its power by focusing on gene sets, that is, groups of genes that share common biological function, chromosomal location, or regulation. We demonstrate how GSEA yields insights into several cancer-related data sets, including leukemia and lung cancer. Notably, where single-gene analysis finds little similarity between two independent studies of patient survival in lung cancer, GSEA reveals many biological pathways in common. The GSEA method is embodied in a freely available software package, together with an initial database of 1,325 biologically defined gene sets.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.

            DNA microarrays can be used to identify gene expression changes characteristic of human disease. This is challenging, however, when relevant differences are subtle at the level of individual genes. We introduce an analytical strategy, Gene Set Enrichment Analysis, designed to detect modest but coordinate changes in the expression of groups of functionally related genes. Using this approach, we identify a set of genes involved in oxidative phosphorylation whose expression is coordinately decreased in human diabetic muscle. Expression of these genes is high at sites of insulin-mediated glucose disposal, activated by PGC-1alpha and correlated with total-body aerobic capacity. Our results associate this gene set with clinically important variation in human metabolism and illustrate the value of pathway relationships in the analysis of genomic profiling experiments.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

              A revision of the nearly 8-year-old World Health Organization classification of the lymphoid neoplasms and the accompanying monograph is being published. It reflects a consensus among hematopathologists, geneticists, and clinicians regarding both updates to current entities as well as the addition of a limited number of new provisional entities. The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies. The major changes are reviewed with an emphasis on the most important advances in our understanding that impact our diagnostic approach, clinical expectations, and therapeutic strategies for the lymphoid neoplasms.
                Bookmark

                Author and article information

                Contributors
                naoya@is.icc.u-tokai.ac.jp
                Journal
                Cancer Sci
                Cancer Sci
                10.1111/(ISSN)1349-7006
                CAS
                Cancer Science
                John Wiley and Sons Inc. (Hoboken )
                1347-9032
                1349-7006
                29 November 2021
                January 2022
                : 113
                : 1 ( doiID: 10.1111/cas.v113.1 )
                : 334-348
                Affiliations
                [ 1 ] Department of Pathology School of Medicine Tokai University Isehara Japan
                [ 2 ] Monoclonal Antibodies Core Unit Spanish National Cancer Research Center (CNIO) Madrid Spain
                [ 3 ] Department of Pathology Hospital Clinic Barcelona University of Barcelona August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Barcelona Spain
                [ 4 ] Department of Pathology Hospital del Mar The Hospital del Mar Medical Research Institute (IMIM) Barcelona Spain
                [ 5 ] Sharjah Institute for Medical Research Department of Clinical Sciences College of Medicine University of Sharjah Sharjah United Arab Emirates
                [ 6 ] Division of Surgery and Interventional Science University College London London UK
                [ 7 ] Department of Hematology and Oncology School of Medicine Tokai University Isehara Japan
                Author notes
                [*] [* ] Correspondence

                Naoya Nakamura, Department of Pathology, Tokai University, School of Medicine, 143 Shimokasuya, Isehara‐shi, Kanagawa 259‐1193, Japan.

                Email: naoya@ 123456is.icc.u-tokai.ac.jp

                Author information
                https://orcid.org/0000-0002-6129-8299
                https://orcid.org/0000-0003-3358-5845
                https://orcid.org/0000-0002-0650-7609
                https://orcid.org/0000-0002-9807-2875
                https://orcid.org/0000-0003-0790-9017
                https://orcid.org/0000-0001-5236-5085
                https://orcid.org/0000-0002-1402-0868
                https://orcid.org/0000-0003-4332-5254
                Article
                CAS15179
                10.1111/cas.15179
                8748251
                34706126
                37305059-56db-439a-9f5e-56990479c400
                © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 19 October 2021
                : 14 June 2021
                : 20 October 2021
                Page count
                Figures: 6, Tables: 8, Pages: 15, Words: 10130
                Funding
                Funded by: Japan Society for the Promotion of Science , doi 10.13039/501100001691;
                Award ID: KAKEN 15K19061
                Award ID: KAKEN 18K15100
                Award ID: KAKEN 24590430
                Funded by: University of Sharjah , doi 10.13039/100016714;
                Award ID: 1901090258
                Funded by: Sharjah Research Academy , doi 10.13039/501100016155;
                Award ID: MED001
                Funded by: Tokai University , doi 10.13039/501100010655;
                Award ID: Postdoctoral Research Fellowship
                Award ID: Research incentive assistant plan 2021‐B04
                Funded by: Al‐Jalila Foundation , doi 10.13039/100012001;
                Award ID: AJF201741
                Categories
                Original Article
                Original Articles
                Pathology
                Custom metadata
                2.0
                January 2022
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.7.0 mode:remove_FC converted:10.01.2022

                Oncology & Radiotherapy
                diffuse large b‐cell lymphoma,il‐10,pd‐l1, cd163,ptx3
                Oncology & Radiotherapy
                diffuse large b‐cell lymphoma, il‐10, pd‐l1, cd163, ptx3

                Comments

                Comment on this article